<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetol Metab Syndr</journal-id><journal-id journal-id-type="iso-abbrev">Diabetol Metab Syndr</journal-id><journal-title-group><journal-title>Diabetology &amp; Metabolic Syndrome</journal-title></journal-title-group><issn pub-type="epub">1758-5996</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6543623</article-id><article-id pub-id-type="publisher-id">438</article-id><article-id pub-id-type="doi">10.1186/s13098-019-0438-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2669-1642</contrib-id><name><surname>Anholm</surname><given-names>Christian</given-names></name><address><phone>+45 20847285</phone><email>canholm@youmail.dk</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kumarathurai</surname><given-names>Preman</given-names></name><address><email>preman@kumarathurai.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>J&#252;rs</surname><given-names>Anders</given-names></name><address><email>andersjurs@gmail.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Pedersen</surname><given-names>Lene R&#248;rholm</given-names></name><address><email>lrpd@regionsjaelland.dk</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Nielsen</surname><given-names>Olav Wendelboe</given-names></name><address><email>own@dadlnet.dk</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kristiansen</surname><given-names>Ole Peter</given-names></name><address><email>ole.peter.kristiansen@regionh.dk</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Fenger</surname><given-names>Mogens</given-names></name><address><email>mogens.fenger@regionh.dk</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Holst</surname><given-names>Jens Juul</given-names></name><address><email>jjholst@sund.ku.dk</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Madsbad</surname><given-names>Sten</given-names></name><address><email>sten.madsbad@regionh.dk</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Sajadieh</surname><given-names>Ahmad</given-names></name><address><email>asajadieh@yahoo.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Haugaard</surname><given-names>Steen Bendix</given-names></name><address><email>sbhau@dadlnet.dk</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.475435.4</institution-id><institution>Department of Internal Medicine, </institution><institution>Copenhagen University Hospital Glostrup, </institution></institution-wrap>Nordre Ringvej 57, 2600 Glostrup, Denmark </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9350 8874</institution-id><institution-id institution-id-type="GRID">grid.411702.1</institution-id><institution>Department of Cardiology, </institution><institution>Copenhagen University Hospital Bispebjerg, </institution></institution-wrap>Copenhagen, Denmark </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0646 8202</institution-id><institution-id institution-id-type="GRID">grid.411905.8</institution-id><institution>Department of Clinical Biochemistry, </institution><institution>Copenhagen University Hospital Hvidovre, </institution></institution-wrap>Copenhagen, Denmark </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0674 042X</institution-id><institution-id institution-id-type="GRID">grid.5254.6</institution-id><institution>NovoNordisk Foundation Center for Metabolic Research and Department of Biomedical Sciences, Panum Institute, </institution><institution>University of Copenhagen, </institution></institution-wrap>Copenhagen, Denmark </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0646 8202</institution-id><institution-id institution-id-type="GRID">grid.411905.8</institution-id><institution>Department of Endocrinology, </institution><institution>Copenhagen University Hospital Hvidovre, </institution></institution-wrap>Copenhagen, Denmark </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9350 8874</institution-id><institution-id institution-id-type="GRID">grid.411702.1</institution-id><institution>Department of Endocrinology I, </institution><institution>Copenhagen University Hospital Bispebjerg, </institution></institution-wrap>Copenhagen, Denmark </aff></contrib-group><pub-date pub-type="epub"><day>31</day><month>5</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>31</day><month>5</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>11</volume><elocation-id>42</elocation-id><history><date date-type="received"><day>25</day><month>2</month><year>2019</year></date><date date-type="accepted"><day>17</day><month>5</month><year>2019</year></date></history><permissions><copyright-statement>&#169; The Author(s) 2019</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Hyperinsulinemia aggravates insulin resistance and cardio-vascular disease. How the insulinotropic glucagon-like peptide-1 receptor agonist liraglutide in a physiologic post-prandial setting may act on pancreatic alpha and beta-cell function in patients with coronary artery disease (CAD) and type 2 diabetes (T2DM) is less clear.</p></sec><sec><title>Methods</title><p id="Par2">Insulin resistant patients with established CAD and newly diagnosed well-controlled T2DM were recruited to a placebo-controlled, cross-over trial with two treatment periods of 12&#160;weeks and a 2&#160;weeks wash-out period before and in-between. Treatment was liraglutide or placebo titrated from 0.6&#160;mg q.d. to 1.8&#160;mg q.d. within 4&#160;weeks and metformin titrated from 500&#160;mg b.i.d to 1000&#160;mg b.i.d. within 4&#160;weeks. Before and after intervention in both 12&#160;weeks periods insulin, C-peptide, glucose, and glucagon were measured during a meal test. Beta-cell function derived from the oral glucose tolerance setting was calculated as changes in insulin secretion per unit changes in glucose concentration (B<sub>total</sub>) and whole-body insulin resistance using ISI<sub>composite</sub>.</p></sec><sec><title>Results</title><p id="Par3">Liraglutide increased the disposition index [B<sub>total</sub>&#8201;&#215;&#8201;ISI<sub>composite</sub>, by 40% (n&#8201;=&#8201;24, p&#8201;&lt;&#8201;0.001)] compared to placebo. Post-prandial insulin and glucose was reduced by metformin in combination with liraglutide and differed, but not significantly different from placebo, moreover, glucagon concentration was unaffected. Additionally, insulin clearance tended to increase during liraglutide therapy (n&#8201;=&#8201;26, p&#8201;=&#8201;0.06).</p></sec><sec><title>Conclusions</title><p id="Par4">The insulinotropic drug liraglutide may without increasing the insulin concentration reduce postprandial glucose but not glucagon excursions and improve beta-cell function in newly diagnosed and well-controlled T2DM.</p><p id="Par5"><italic>Trial registration</italic> Clinicaltrials.gov ID: NCT01595789</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>GLP1-receptor agonist</kwd><kwd>Diabetes mellitus type 2</kwd><kwd>Beta-cell function</kwd><kwd>Insulin sensitivity</kwd><kwd>Meal test</kwd><kwd>Insulin clearance</kwd><kwd>Glucagon</kwd></kwd-group><funding-group><award-group><funding-source><institution>Novo Nordisk (DK)</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007405</institution-id><institution>Hjerteforeningen</institution></institution-wrap></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100005747</institution-id><institution>A.P. M&#248;ller og Hustru Chastine Mc-Kinney M&#248;llers Fond til almene Formaal</institution></institution-wrap></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Dept. of internal medicine, University Hospital of Copenhagen Amager</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>The Clinical Research Center, University Hospital of Copenhagen Hvidovre</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>The Bispebjerg Hospital Research Foundation</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; The Author(s) 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par23">The hyperglycemia in type 2 diabetes mellitus (T2DM) results from an imbalance between insulin secretion and insulin sensitivity [<xref ref-type="bibr" rid="CR1">1</xref>] with impaired insulin action and an insufficient and delayed insulin response during meals as well as an inappropriate glucagon secretion [<xref ref-type="bibr" rid="CR2">2</xref>]. Fasting as well as postprandial glucagon secretion increase progressively through the spectrum of impaired glucose tolerance to manifest T2DM [<xref ref-type="bibr" rid="CR3">3</xref>]. The hyperglucagonemia is associated with hepatic insulin resistance [<xref ref-type="bibr" rid="CR4">4</xref>] and an increased hepatic glucose production [<xref ref-type="bibr" rid="CR5">5</xref>]. Elevated levels of non-esterified fatty acids (NEFA) resulting from adipose tissue insulin resistance may play a role in the development of peripheral as well as hepatic insulin resistance and may also impair beta-cell function in T2DM and in obese prediabetic individuals [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par24">Metformin, which is recommended as first line therapy in patients with T2DM [<xref ref-type="bibr" rid="CR7">7</xref>], has beneficial effects on HbA1c, body weight, cardiovascular mortality [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>] and insulin sensitivity [<xref ref-type="bibr" rid="CR9">9</xref>]. However, metformin treatment has no effect on glucagon levels [<xref ref-type="bibr" rid="CR10">10</xref>], whereas GLP-1 receptor agonists (GLP-1RA) have been suggested to inhibit glucagon secretion from alpha-cells [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Furthermore, therapy with GLP1-RA is associated with a potentiation of glucose induced insulin secretion and a modest weight loss [<xref ref-type="bibr" rid="CR13">13</xref>] and as a result it effectively reduces hyperglycemia in patients with T2DM [<xref ref-type="bibr" rid="CR14">14</xref>]. This antihyperglycemic action of the GLP1-RA liraglutide is well-established in patients with longstanding not well-controlled diabetes [<xref ref-type="bibr" rid="CR15">15</xref>&#8211;<xref ref-type="bibr" rid="CR19">19</xref>]. The effect of GLP-1 receptor agonist on insulin sensitivity is still discussed [<xref ref-type="bibr" rid="CR20">20</xref>&#8211;<xref ref-type="bibr" rid="CR22">22</xref>], and its effect on insulin clearance is sparsely examined [<xref ref-type="bibr" rid="CR23">23</xref>]. Newly diagnosed T2DM in patients with coronary artery disease (CAD) is associated with excess mortality [<xref ref-type="bibr" rid="CR24">24</xref>]. Accordingly, it would be of interest how liraglutide may improve postprandial glycaemia and insulinemia in a population of newly diagnosed well-controlled T2DM subjects with CAD, particularly considering that liraglutide is insulinotropic.</p><p id="Par25">The aims of the present study, therefore, were to evaluate effects of the GLP-1 RA liraglutide in combination with metformin on indices of alpha- and beta-cell function, insulin sensitivity and insulin clearance. This was evaluated using a mixed meal test in obese patients with newly diagnosed, well-controlled T2DM and high cardiovascular risk, a population in which efficacy of antidiabetic medication is essential and where several recent guidelines recommend GLP-1 RA, e.g. liraglutide as drug number 2 after metformin [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR25">25</xref>].</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Subjects</title><p id="Par26">The inclusion criteria were stable coronary artery disease (CAD), body mass index (BMI)&#8201;&#8805;&#8201;25&#160;kg/m<sup>2</sup>, age&#8201;&#8805;&#8201;18 and&#8201;&#8804;&#8201;85&#160;years, and newly diagnosed (&lt;&#8201;2&#160;years) T2DM according to the criteria defined by the American Diabetes Association [<xref ref-type="bibr" rid="CR26">26</xref>]. To be included, the patients were to be treated with diet, metformin or sulfonylurea alone or in combinations. All oral antidiabetic medications were stopped 2&#160;weeks before baseline visit (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Exclusion criteria were, amongst others, previous treatment with a GLP-1RA or dipeptidyl peptidase-4 inhibitor. A comprehensive list of the exclusion criteria can be found elsewhere [<xref ref-type="bibr" rid="CR27">27</xref>].<table-wrap id="Tab1"><label>Table&#160;1</label><caption><p>Baseline characteristics of the study population, in median (IQR)</p></caption><table-wrap-foot><p><sup>a</sup>Mean (SD)</p><p><sup>b</sup>Anti diabetic treatment</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec4"><title>Design</title><p id="Par27">The study was an investigator-initiated, double-blind, randomized, placebo-controlled, cross-over trial. Details of the design, participants and intervention have been described previously [<xref ref-type="bibr" rid="CR27">27</xref>].</p><p id="Par28">Patients meeting the inclusion criteria were included consecutively and study drugs in subject boxes were sequentially numbered with a unique code and randomized by computer in a 1:1 randomization ratio by Novo Nordisk A/S and allocation sequence was concealed until all participants had completed the study [<xref ref-type="bibr" rid="CR27">27</xref>]. Enrollment and assignment of participants were done at Department of Cardiology, Copenhagen University Hospital, Bispebjerg, Denmark. Patients were recruited from May 2012 to October 2014.</p></sec><sec id="Sec5"><title>Intervention</title><p id="Par29">Liraglutide and metformin versus placebo and metformin in 12 plus 12&#160;weeks with a 2-week wash-out period. The study period for each patient was 26&#160;weeks and consisted of 4 major visits (at weeks 0, 12, 14 and 26); the wash-out was between weeks 12 and 14. Liraglutide dose was 1.8&#160;mg once daily subcutaneously (titrated from 0.6&#160;mg to 1.8&#160;mg once daily within 4&#160;weeks) and metformin 1&#160;g twice daily orally (titrated from 500&#160;mg twice daily to 1&#160;g twice daily in 4&#160;weeks) [<xref ref-type="bibr" rid="CR27">27</xref>]. The last injection of liraglutide was in the morning on test days. Data collection was carried out in Department of Cardiology, Copenhagen University Hospital, Bispebjerg, Denmark.</p></sec><sec id="Sec6"><title>Endpoints</title><p id="Par30">Beta-cell function (as measured by disposition index), insulin sensitivity, insulin clearance and responses of glucose, insulin, C-peptide, glucagon and NEFA during a 2-h mixed meal tolerance test, respectively. Treatment effects were evaluated by comparing results from the visits at initiation and end of each treatment period.</p></sec><sec id="Sec7"><title>Mixed meal test</title><p id="Par31">A 375-g solid meal consisting of 60-g (46 E%) carbohydrates, 38-g (28 E%) protein and 16-g (26 E%) fat, equivalent to 550&#160;kcal was consumed after an overnight fasting period of 10&#160;h. Baseline blood samples were obtained at 10, 5 and 1&#160;min before and 30, 60, 90 and 120&#160;min after initiation of the test meal, which was to be finished within 15&#160;min.</p></sec><sec id="Sec8"><title>Assay</title><p id="Par32">Glucose measurements were carried out using an Accu-Chek Inform II meter (Roche, Swiss). Coefficient of variance (CV) was&#8201;&#8804;&#8201;3.3% for glucose levels&#8201;&gt;&#8201;4.2&#160;mmol/l. Plasma insulin and C-peptide concentrations (pmol/l) were determined by the enzyme-linked immunosorbent assay (ELISA) (Siemens Healthcare Diagnostics, LA, California, USA), for insulin with an intra-assay CV of 3.3&#8211;5.5% and an inter-assay CV of 4.1&#8211;7.3% and for C-peptide with an intra-assay CV of 1.7&#8211;2.3% and an inter-assay CV of 2.9&#8211;4.8%. Plasma NEFA (mmol/l) was measured by an enzymatic test (Wako Chemicals, Neuss, Germany) with a median intra-assay CV of 1.5% and a median inter-assay CV of 7.5%. Glucagon concentrations in plasma were measured after extraction of plasma with 70% ethanol (vol./vol., final concentration). The antibody employed (code no. 4305) is directed against the C-terminus of the glucagon molecule and therefore mainly measures glucagon of pancreatic origin [<xref ref-type="bibr" rid="CR28">28</xref>]. Standards were human glucagon and tracer was monoiodinated human glucagon (both gifts from Novo Nordisk, Bagsv&#230;rd, Denmark). Sensitivity and detection limit is below 1&#160;pmol/l, intra-assay CV below 6% at 20&#8211;30&#160;pmol/l, and recovery of standard, added to plasma before extraction, about 100% when corrected for losses inherent in the plasma extraction procedure [<xref ref-type="bibr" rid="CR29">29</xref>].</p></sec><sec id="Sec9"><title>Calculations</title><p id="Par33">The composite measure of whole body insulin sensitivity (ISI<sub>Composite</sub>) [<xref ref-type="bibr" rid="CR30">30</xref>] and the homeostasis model assessment of insulin resistance (HOMA-IR) [<xref ref-type="bibr" rid="CR31">31</xref>] were determined as follows:<disp-formula id="Equa"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ISI_{composite} = \frac{10,000}{{\sqrt {\left( {FPG \times FPI} \right) \times \left( {\bar{G} \times \bar{I}} \right)} }}\quad HOMA{-}IR = \frac{{\left( {FPG \times FPI} \right)}}{405}$$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi mathvariant="italic">composite</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>10</mml:mn><mml:mo>,</mml:mo><mml:mn>000</mml:mn></mml:mrow><mml:msqrt><mml:mrow><mml:mfenced close=")" open="(" separators=""><mml:mrow><mml:mi>F</mml:mi><mml:mi>P</mml:mi><mml:mi>G</mml:mi><mml:mo>&#215;</mml:mo><mml:mi>F</mml:mi><mml:mi>P</mml:mi><mml:mi>I</mml:mi></mml:mrow></mml:mfenced><mml:mo>&#215;</mml:mo><mml:mfenced close=")" open="(" separators=""><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">&#175;</mml:mo></mml:mrow></mml:mover><mml:mo>&#215;</mml:mo><mml:mover accent="true"><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">&#175;</mml:mo></mml:mrow></mml:mover></mml:mrow></mml:mfenced></mml:mrow></mml:msqrt></mml:mfrac><mml:mspace width="1em"/><mml:mi>H</mml:mi><mml:mi>O</mml:mi><mml:mi>M</mml:mi><mml:mi>A</mml:mi><mml:mo>-</mml:mo><mml:mi>I</mml:mi><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mfenced close=")" open="(" separators=""><mml:mrow><mml:mi>F</mml:mi><mml:mi>P</mml:mi><mml:mi>G</mml:mi><mml:mo>&#215;</mml:mo><mml:mi>F</mml:mi><mml:mi>P</mml:mi><mml:mi>I</mml:mi></mml:mrow></mml:mfenced><mml:mn>405</mml:mn></mml:mfrac></mml:mrow></mml:math><graphic xlink:href="13098_2019_438_Article_Equa.gif" position="anchor"/></alternatives></disp-formula>in which FPI is fasting plasma insulin (&#956;U/ml), <inline-formula id="IEq1"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\bar{\text{I}}}$$\end{document}</tex-math><mml:math id="M4"><mml:mover accent="true"><mml:mrow><mml:mtext>I</mml:mtext></mml:mrow><mml:mrow><mml:mo stretchy="false">&#175;</mml:mo></mml:mrow></mml:mover></mml:math><inline-graphic xlink:href="13098_2019_438_Article_IEq1.gif"/></alternatives></inline-formula> is mean plasma insulin, FPG is fasting plasma glucose (mg/dl) and <inline-formula id="IEq2"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\bar{\text{G}}}$$\end{document}</tex-math><mml:math id="M6"><mml:mover accent="true"><mml:mrow><mml:mtext>G</mml:mtext></mml:mrow><mml:mrow><mml:mo stretchy="false">&#175;</mml:mo></mml:mrow></mml:mover></mml:math><inline-graphic xlink:href="13098_2019_438_Article_IEq2.gif"/></alternatives></inline-formula> is mean plasma glucose during meal test.</p><p id="Par34">Prehepatic insulin secretion rates (ISR) (pmol/kg/min) were calculated from plasma C-peptide concentrations using the ISEC (Insulin SECretion) computer program [<xref ref-type="bibr" rid="CR32">32</xref>]. This method is based upon the assumptions that C-peptide is not cleared by the liver and is co-secreted with insulin in equimolar amounts from the pancreas. The beta-cell response to changes in glucose during a meal test expresses the efficacy by which changes in plasma glucose concentrations stimulate insulin secretion. This relationship between changes in plasma glucose concentrations and ISR during the meal test was evaluated by cross-correlation analysis, and the slope of the regression lines (B<sub>Total</sub>) is a measure of the change in insulin secretion per unit change in glucose concentration, i.e. beta cell sensitivity to glucose or beta-cell responsiveness. Beta-cell function was defined as the product of beta-cell responsiveness and insulin sensitivity, i.e. the disposition index (D<sub>i</sub>) [<xref ref-type="bibr" rid="CR33">33</xref>], i.e. assuming a hyperbolic association between beta-cell responsiveness and insulin sensitivity<disp-formula id="Equb"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{i} = B_{total} \times {\text{ISI}}_{composite}$$\end{document}</tex-math><mml:math id="M8" display="block"><mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>B</mml:mi><mml:mrow><mml:mi mathvariant="italic">total</mml:mi></mml:mrow></mml:msub><mml:mo>&#215;</mml:mo><mml:msub><mml:mtext>ISI</mml:mtext><mml:mrow><mml:mi mathvariant="italic">composite</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><graphic xlink:href="13098_2019_438_Article_Equb.gif" position="anchor"/></alternatives></disp-formula>We tested for the hyperbolic law in the basal state and found a R<sup>2</sup>&#8201;=&#8201;0.81 suggesting that the disposition index may be valid to use in the present study.</p><p id="Par35">The trapezoidal rule [<xref ref-type="bibr" rid="CR34">34</xref>] was used to calculate the area under the curve (AUC) for ISR, insulin, glucose and NEFA concentrations. The integer of ISR (AUC&#8201;&#8722;&#8201;ISR<sub>0&#8211;120&#160;min</sub>) represents the total amount of insulin secreted throughout the meal test while the integer of insulin concentration profiles during the meal test (AUC&#8201;&#8722;&#8201;insulin<sub>0&#8211;120&#160;min</sub>) represents both insulin secretion and insulin clearance. Thus, the ratio of these integers adjusted for total body mass reflects insulin clearance (MCRi):<disp-formula id="Equc"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$MCRi = \frac{{AUC - ISR_{0 - 120\,min} }}{{AUC - Insulin_{0 - 120\,min} }} \times Total\,body\,mass$$\end{document}</tex-math><mml:math id="M10" display="block"><mml:mrow><mml:mi>M</mml:mi><mml:mi>C</mml:mi><mml:mi>R</mml:mi><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi><mml:mo>-</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>-</mml:mo><mml:mn>120</mml:mn><mml:mspace width="0.166667em"/><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi><mml:mo>-</mml:mo><mml:mi>I</mml:mi><mml:mi>n</mml:mi><mml:mi>s</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>-</mml:mo><mml:mn>120</mml:mn><mml:mspace width="0.166667em"/><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>&#215;</mml:mo><mml:mi>T</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mspace width="0.166667em"/><mml:mi>b</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>y</mml:mi><mml:mspace width="0.166667em"/><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:math><graphic xlink:href="13098_2019_438_Article_Equc.gif" position="anchor"/></alternatives></disp-formula>Plasma insulin levels are at steady-state in the basal period, therefore the posthepatic insulin delivery rate (IDR<sub>Basal</sub>) can be calculated as [<xref ref-type="bibr" rid="CR35">35</xref>]:<disp-formula id="Equd"><alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$IDR_{Basal} = insulin_{Basal} \times MCRi$$\end{document}</tex-math><mml:math id="M12" display="block"><mml:mrow><mml:mi>I</mml:mi><mml:mi>D</mml:mi><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi mathvariant="italic">Basal</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>s</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mi mathvariant="italic">Basal</mml:mi></mml:mrow></mml:msub><mml:mo>&#215;</mml:mo><mml:mi>M</mml:mi><mml:mi>C</mml:mi><mml:mi>R</mml:mi><mml:mi>i</mml:mi></mml:mrow></mml:math><graphic xlink:href="13098_2019_438_Article_Equd.gif" position="anchor"/></alternatives></disp-formula>The ratio of the IDR<sub>Basal</sub> to the ISR<sub>Basal</sub> is the fraction of insulin not extracted by the liver, therefore the hepatic extraction of insulin (HEXi) is calculated as [<xref ref-type="bibr" rid="CR35">35</xref>]:<disp-formula id="Eque"><alternatives><tex-math id="M13">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$HEXi = 1 - \frac{{IDR_{Basal} }}{{ISR_{Basal} }}$$\end{document}</tex-math><mml:math id="M14" display="block"><mml:mrow><mml:mi>H</mml:mi><mml:mi>E</mml:mi><mml:mi>X</mml:mi><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:mi>I</mml:mi><mml:mi>D</mml:mi><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi mathvariant="italic">Basal</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi mathvariant="italic">Basal</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:math><graphic xlink:href="13098_2019_438_Article_Eque.gif" position="anchor"/></alternatives></disp-formula>To evaluate the efficacy of insulin to suppress NEFA production [<xref ref-type="bibr" rid="CR36">36</xref>] we divided &#8710;AUC&#8201;&#8722;&#8201;NEFA<sub>0&#8211;120&#160;min</sub> by &#8710;AUC&#8201;&#8722;&#8201;insulin<sub>0&#8211;120&#160;min</sub>, (denoted NEFA<sub>ins</sub>).</p></sec><sec id="Sec10"><title>Statistical analysis</title><p id="Par36">Data are reported as median (IQR) or mean (SD). Students&#8217; paired t-test was used for normally distributed data when comparing groups. In non-normally distributed data, Wilcoxon&#8217;s Signed Rank test was used. A two-sided value of p&#8201;&lt;&#8201;0.05 was considered statistically significant. Comprehensive details on the power calculation are published elsewhere [<xref ref-type="bibr" rid="CR27">27</xref>]. Statistical analyses were performed with SAS 9.4 (SAS Institute Inc., Cary, North Carolina, USA). The study was approved by the Regional Committee on Biomedical Research Ethics of the Capital Region of Denmark and was carried out in accordance with the International Conference on Harmonization&#8212;Good Clinical Practice standards and informed consent was obtained from all participants. The study protocol was registered at Clinicaltrials.gov with ID: NCT01595789.</p></sec></sec><sec id="Sec11"><title>Results</title><sec id="Sec12"><title>Participants</title><p id="Par37">Of the 41 patients randomized, two patients declined to participate before first visit and nine patients discontinued the study (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Twenty-eight patients completed all study visits. Two patients treated with placebo in the first period could not attend visit 3 therefore data from visit 2 were carried forward and used as baseline for the second period. Thus, thirty participants were included in the paired analyses. Eliminating data from the two patients did not influence the main results. Baseline characteristics are found in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. Calculations of indices were limited by missing values in a few patients, thereby leading to patients&#8201;&lt;&#8201;30 (Tables&#160;<xref rid="Tab2" ref-type="table">2</xref>, <xref rid="Tab3" ref-type="table">3</xref>). At baseline mean HbA1c was 47 [<xref ref-type="bibr" rid="CR6">6</xref>] mmol/mol.<fig id="Fig1"><label>Fig.&#160;1</label><caption><p>Screening, randomization and follow-up [<xref ref-type="bibr" rid="CR39">39</xref>]</p></caption><graphic xlink:href="13098_2019_438_Fig1_HTML" id="MO6"/></fig>
<table-wrap id="Tab2"><label>Table&#160;2</label><caption><p>Indices of beta-cell function, insulin sensitivity and clearance</p></caption><table-wrap-foot><p>Units are mmol/l&#8201;&#215;&#8201;<sup>120</sup>min except for insulin secretion rate (ISR) measured i pmol/kg. Data reported as median (IQR)</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab3"><label>Table&#160;3</label><caption><p>Area under the curve (AUC) in median (IQR), units are mmol/l&#8201;&#215;&#8201;<sup>120</sup>min except ISR measured in pmol/kg</p></caption></table-wrap>
</p></sec><sec id="Sec13"><title>Alpha-cell function</title><p id="Par38">Baseline fasting p-glucagon was 5.3 (3.5) pmol/l. Both placebo and liraglutide treatment increased fasting glucagon levels to 7.5 (3.8) pmol/l (p&#8201;&lt;&#8201;0.001) and 6.8 (3.1) pmol/l (p&#8201;&lt;&#8201;0.002), respectively, but with no significant difference between periods (p&#8201;&lt;&#8201;0.7). AUC<sub>glucagon</sub> was not significantly changed by placebo treatment [1138 (663) to 1283 (637) pmol/l&#8201;&#215;&#8201;<sup>120</sup>min (p&#8201;=&#8201;0.07)], and neither did liraglutide treatment affect AUC<sub>glucagon</sub> [992 (516) to 995 (417) pmol/l&#8201;&#215;&#8201;<sup>120</sup>min (p&#8201;=&#8201;0.64)], and no difference between treatments was observed (p&#8201;&lt;&#8201;0.4). AUC<sub>insulin/glucagon</sub> was reduced by placebo (p&#8201;=&#8201;0.01) but not by liraglutide treatment (p&#8201;&lt;&#8201;0.06) and with no difference between treatment periods (p&#8201;=&#8201;0.09) (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig.&#160;2</label><caption><p>Plasma levels of glucose (<bold>a</bold>), C-peptide (<bold>b</bold>), insulin (<bold>c</bold>), insulin secretion rates (<bold>d</bold>), glucagon (<bold>e</bold>) and NEFA (<bold>f</bold>) during meal test</p></caption><graphic xlink:href="13098_2019_438_Fig2_HTML" id="MO7"/></fig>
</p></sec><sec id="Sec14"><title>Insulin sensitivity</title><p id="Par39">ISI-composite (ISI<sub>comp</sub>) was increased in both treatment periods: placebo; 0.73 (&#8722;&#8201;0.05 to 2.31) l<sup>2</sup>/mg/microU (p&#8201;&lt;&#8201;0.0005) and liraglutide; 1.68 (0.57 to 3.34) l<sup>2</sup>/mg/microU (p&#8201;&lt;&#8201;0.0001), with no significant differences between treatments (p&#8201;=&#8201;0.14). HOMA-IR was reduced significantly in both placebo and the liraglutide period but with no differences between treatments (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>).</p></sec><sec id="Sec15"><title>Beta-cell function and plasma glucose</title><p id="Par40">AUC<sub>glucose</sub> was reduced in both placebo and liraglutide periods by &#8722;&#8201;76 (&#8722;&#8201;144 to &#8722;&#8201;29) mmol/l&#8201;&#215;&#8201;<sup>120</sup>min and &#8722;&#8201;106 (&#8722;&#8201;213 to &#8722;&#8201;41) mmol/l&#8201;&#215;&#8201;<sup>120</sup>min, p&#8201;=&#8201;0.0003 vs. p&#8201;&lt;&#8201;0.0001, respectively, with no difference between treatments (Table&#160;<xref rid="Tab3" ref-type="table">3</xref> and Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). Insulin and C-peptide responses are depicted in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>. Analysis of AUC&#8217;s showed significant reductions of AUC<sub>insulin</sub> in both placebo and liraglutide periods with no significant difference between treatments (p&#8201;&lt;&#8201;0.46) (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). Additionally, the AUC insulin/glucose ratio was not increased by liraglutide treatment: &#8722;&#8201;50 (312) pmol/mmol (p&#8201;=&#8201;0.4).</p><p id="Par41">Basal insulin delivery rates (IDR<sub>basal</sub>) were not affected by either treatment (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). AUC<sub>ISR</sub> was significantly reduced only in the placebo period, with no additional change observed with liraglutide treatment (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). Paired analysis (n&#8201;=&#8201;25) did not reveal significant differences in ISR between placebo and liraglutide treatment (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). Beta-cell responsiveness (B<sub>total</sub>) did not differ between treatments (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). Disposition index (DI) was improved in the liraglutide period; 6.0 (2.78 to 9.23), p&#8201;&lt;&#8201;0.0001, whereas placebo treatment did not affect DI significantly. Paired analysis revealed an effect of liraglutide therapy of 3.35 (&#8722;&#8201;0.51 to 9.29), p&#8201;=&#8201;0.0005, improving baseline value by 40% (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>) towards a less diabetic state (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). Of importance we observed a strong baseline hyperbolic association between ISI<sub>comp</sub> and B<sub>total</sub> of R<sup>2</sup>&#8201;=&#8201;0.81, which comply with the data that was obtained in the original method study on this relationship using intravenous glucose defining the beta-cell function [<xref ref-type="bibr" rid="CR37">37</xref>].<fig id="Fig3"><label>Fig.&#160;3</label><caption><p>The hyperbolic relationship between B<sub>total</sub> and ISI<sub>Composite</sub>&#8212;Open circles represents all pretreatment values, i.e. baseline values combined with values after wash-out before beginning of period 2. The hyperbolic function is evident for both groups and for all pretreatment values. Fitted (all); R<sup>2</sup>&#8201;=&#8201;0.81, fitted (baseline):R<sup>2</sup>&#8201;=&#8201;0.8, fitted (washout); R<sup>2</sup>&#8201;=&#8201;0.83. Treatment effect is indicated by square and triangle (liraglutide vs. placebo), beginning and end of treatment are depicted by arrows</p></caption><graphic xlink:href="13098_2019_438_Fig3_HTML" id="MO8"/></fig>
</p></sec><sec id="Sec16"><title>Insulin clearance</title><p id="Par42">Baseline fasting insulin was inversely correlated to MCRi<sub>kg</sub> (R<sup>2</sup>&#8201;=&#8201;0.58, p&#8201;&lt;&#8201;0.0001), MCRi<sub>total</sub> (R<sup>2</sup>&#8201;=&#8201;0.33, p&#8201;=&#8201;0.001) and HEXi (R<sup>2</sup>&#8201;=&#8201;0.31, p&#8201;&lt;&#8201;0.002). In the placebo period MCRi<sub>kg</sub> was numerically but non-significantly increased but the combination of liraglutide and metformin increased MCRi<sub>kg</sub> significantly by 3.56 (0.29 to 7.02)&#8201;&#215;&#8201;10<sup>&#8722;3</sup> L/kg/min (p&#8201;=&#8201;0.005) with a borderline difference between groups (p&#8201;=&#8201;0.06) (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). Improvement in ISI<sub>comp</sub> was associated with reduction in MCRi<sub>kg</sub> (R<sup>2</sup>&#8201;=&#8201;0.21, p&#8201;=&#8201;0.02) and MCRi<sub>total</sub> (R<sup>2</sup>&#8201;=&#8201;0.24, p&#8201;=&#8201;0.01). There were no associations with HOMA-IR. Baseline HEXi was reduced as compared to normoglycemic subjects who usually clear app. 50% or more during the first pass of the liver [<xref ref-type="bibr" rid="CR38">38</xref>]. These patients exhibit a HEXi of only 29% (21 to 36%) and liraglutide therapy had no effect on HEXi.</p><p id="Par43">A subgroup analysis of the 24 patients with complete data set with respect to: B<sub>total</sub>, ISI<sub>comp</sub>, DI, HOMA-IR, MCRi<sub>kg/total</sub> and HEXi confirmed the results outlined previously. However, regarding MCRi<sub>kg</sub> the effects of liraglutide and placebo were comparable to the analysis based on all patients, nevertheless, the placebo corrected difference reached statistical significance (p&#8201;=&#8201;0.03).</p></sec><sec id="Sec17"><title>NEFA</title><p id="Par44">Baseline fasting NEFA did not correlate to weight, BMI or HOMA-IR. AUC<sub>NEFA</sub> did not change significantly in the placebo period in contrast to the liraglutide period in which AUC<sub>NEFA</sub> increased significantly, but the difference between the groups was not statistical different (p&#8201;=&#8201;0.13) (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). The amount of insulin required to suppress NEFA production (NEFA<sub>ins</sub>) was not changed significantly in placebo period but was reduced in liraglutide period; &#8722;&#8201;470 (&#8722;&#8201;1790 to 10) nmol/pmol, p&#8201;&lt;&#8201;0.05 (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>).</p></sec><sec id="Sec18"><title>Hba1c and body weight</title><p id="Par45">HbA1c at 47 [<xref ref-type="bibr" rid="CR6">6</xref>] mmol/mol was reduced by &#8722;&#8201;3.3 (6.51) mmol/mol, p&#8201;&lt;&#8201;0.01 and body weight at 93 (85 to 108) kg was reduced by &#8722;&#8201;2.7 (&#8722;&#8201;6.7 to &#8722;&#8201;0.6) kg, p&#8201;=&#8201;0.0004, both corrected for placebo treatment.</p></sec><sec id="Sec19"><title>Explanatory variables and carry-over effect</title><p id="Par46">We found no correlations between weight loss and ISI<sub>comp</sub>; placebo (R<sup>2</sup>&#8201;=&#8201;0.01; p&#8201;&gt;&#8201;0.7) and liraglutide (R<sup>2</sup>&#8201;=&#8201;0.06; p&#8201;&gt;&#8201;0.2) or weight loss and DI; placebo (R<sup>2</sup>&#8201;&lt;&#8201;0.01; p&#8201;&gt;&#8201;0.7) and liraglutide (R<sup>2</sup>&#8201;=&#8201;0.08; p&#8201;&gt;&#8201;0.2). The variance of weight loss was not associated with baseline weight, BMI, age, sequence of treatment, and differences in treatment duration [<xref ref-type="bibr" rid="CR39">39</xref>]. The presence of a possible carry-over effect was estimated using sum values by the t-test [<xref ref-type="bibr" rid="CR40">40</xref>], but we did not find any significant carry-over effect between periods with respect to weight loss (p&#8201;=&#8201;0.4) [<xref ref-type="bibr" rid="CR39">39</xref>], DI (p&#8201;=&#8201;0.4), B<sub>total</sub> (p&#8201;=&#8201;0.1) or ISI<sub>comp</sub> (p&#8201;=&#8201;0.1).</p></sec><sec id="Sec20"><title>Post-hoc power calculation</title><p id="Par47">Power calculation was based on improvement of disposition index during i.v. glucose test as reported earlier [<xref ref-type="bibr" rid="CR39">39</xref>]. In the present paper we report secondary outcomes, and post-hos power analysis were done. Given a power of 80% and a level of significance of p&#8201;&lt;&#8201;0.05 we would be able to detect an increase in Disposition index on&#8201;&gt;&#8201;40% with n&#8201;=&#8201;34 patients in paired analysis. B<sub>Total</sub> an increase on 20% with 28 patients, however, regarding ISI<sub>Composite</sub> we would need n&#8201;=&#8201;134 patient for detecting the same change in paired analysis.</p></sec><sec id="Sec21"><title>Compliance and safety</title><p id="Par48">Use of the study drugs (metformin, liraglutide and placebo) was counted, and compliance to liraglutide/placebo and metformin was&#8201;&gt;&#8201;90% of prescribed dosages with no significant differences between treatment periods. Adverse event frequency was higher in the active treatment periods predominantly due to gastrointestinal side effects. Serious adverse events were observed in a total of 9 cases; 3 in the active period, 4 in the placebo period and 2 in the wash-out period. A detailed description of adverse events is published elsewhere [<xref ref-type="bibr" rid="CR41">41</xref>].</p></sec></sec><sec id="Sec22"><title>Discussion</title><p id="Par49">This meal test study of newly diagnosed well-controlled patients with T2DM and established CAD showed that liraglutide combined with metformin versus metformin (+placebo) significantly improved beta-cell function with a trend towards improved insulin sensitivity. Of note, the combination of the insulinotropic liraglutide and metformin reduced post-prandial insulin levels in face of a reduced glucose excursion, which is a new finding in this setting.</p><p id="Par50">In this population we have already shown by use of an non-physiologic intravenous glucose tolerance test a significant improvement in hyperglycemia and a significant increase in insulin levels [<xref ref-type="bibr" rid="CR39">39</xref>], which was expected as liraglutide is an insulin secretagogue [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par51">However, in the present study we report data from a mixed meal test where we observed a reduction of insulin as well as glucose levels during this physiological test. The effect of liraglutide on beta-cell responsiveness (B<sub>total</sub>) was neutral. These finding might in part be explained by the very well-controlled hyperglycemia with a mean HbA1c of 47&#160;mmol/mol and a baseline fasting plasma glucose on 5.3&#160;mmol/l. Despite these findings the improvement in disposition index is substantial in the present study, just as seen in the non-physiological setting using intravenous glucose as beta-cell stimulation in combination with the so called &#8220;minimal model&#8221; in the same patients [<xref ref-type="bibr" rid="CR39">39</xref>]. The novelty of the present physiologic study is that despite reduction of insulin levels, liraglutide (combined to metformin) retains its strong effect on beta-cell function (i.e. disposition index) in patients with well-controlled T2D and established CAD.</p><p id="Par52">Furthermore, the combination therapy improved insulin clearance and insulin sensitivity, both hepatic and peripheral. In our setup we evaluated basal level of hepatic insulin extraction but did not find effect of liraglutide on this, however basal level was reduced compared to which was previously reported on glucose intolerant subjects [<xref ref-type="bibr" rid="CR42">42</xref>]. Reduced hepatic extraction is the primary cause of high levels of circulating insulin after a glucose load [<xref ref-type="bibr" rid="CR42">42</xref>] and in normoglycemic subjects hepatic extraction is suppressed up to 30% for&#8201;&#8804;&#8201;150&#160;min following a glucose load [<xref ref-type="bibr" rid="CR38">38</xref>] and 40&#8211;50% of secreted insulin is extracted during a standard meal [<xref ref-type="bibr" rid="CR38">38</xref>]. A body weight loss of&#8201;&gt;&#8201;10&#160;kg increased hepatic extraction of insulin [<xref ref-type="bibr" rid="CR43">43</xref>] and the weight loss in our study was only&#8201;&lt;&#8201;3&#160;kg.</p><p id="Par53">A recent Japanese study used a mixed meal test and compared metformin and liraglutide as monotherapy in patients with T2DM, and was able to demonstrate improvements in beta-cell function (measured as disposition index) by liraglutide compared to no effect following metformin therapy [<xref ref-type="bibr" rid="CR44">44</xref>]. An earlier acute study of 11 subjects with type 2 diabetes and with a HbA1c of 6.5&#8201;&#177;&#8201;0.6% a single dose of liraglutide revealed an increase in fasting ISR but post meal AUC<sub>ISR</sub> was unaltered in contrast to AUC<sub>glucose</sub> which was markedly reduced, indicating an improved beta-cell function [<xref ref-type="bibr" rid="CR45">45</xref>].</p><p id="Par54">The effect on the alpha-cell function was unexpected; fasting glucagon levels increased during liraglutide and placebo treatments but neither treatment led to lower glucagon responses during meal test.</p><p id="Par55">Data from the <italic>liraglutide effect and action in diabetes</italic> (LEAD) studies are conflicting with respect to the effect on fasting glucagon levels; in LEAD-3 a decrease of fasting glucagon was found but no effect was observed in LEAD-4 [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. The absent suppression of glucagon in the present study may indicate a somewhat different action of liraglutide on alpha-cell function compared to native GLP-1, which may relate to the duration of treatment, since a short term period of GLP-1-infusion inhibits glucagon secretion [<xref ref-type="bibr" rid="CR46">46</xref>], whereas a long term infusion does not retain the same glucagon suppressive effect [<xref ref-type="bibr" rid="CR20">20</xref>]. However, a previous study on patients with early stage T2DM revealed somewhat ambiguous results [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>], and it is suggested that attention must be paid to the performance of the assay used to measure glucagon, in order to obtain valid results [<xref ref-type="bibr" rid="CR29">29</xref>]. Additionally, the observed differences in glucagon response can to some extend be caused by differences in the composition of the test meals [<xref ref-type="bibr" rid="CR49">49</xref>] and whether a the oral challenge is a mixed meal or glucose [<xref ref-type="bibr" rid="CR50">50</xref>]. It is indicated that postprandial glucagon levels are increased after at mixed meal as compared to glucose alone [<xref ref-type="bibr" rid="CR50">50</xref>]. We therefore speculate that the present setting may implicate a somewhat different glucagon response compared to an oral glucose challenge or, alternatively that subjects with more advanced disease might reveal a different picture.</p><p id="Par56">In T2DM the suppression of NEFA by insulin is diminished and increased NEFA levels impair insulin action and insulin secretion [<xref ref-type="bibr" rid="CR1">1</xref>]. In the present study liraglutide did not change suppression of NEFA compared with metformin but less insulin was needed to suppress postprandial NEFA in the liraglutide arm.</p><p id="Par57">The present results suggest that in well-controlled subjects with type 2 diabetes the positive effect of liraglutide treatment on beta-cell function is clinically relevant but the effect on alpha cell function is subtle. Additionally, the combination of liraglutide with metformin improves insulin sensitivity and clearance and no effect on post-meal hepatic extraction of insulin. However, it is emphasized that liraglutide may produce another metabolic response in patients with less well-controlled and more advanced diabetes patients, which limits the generalization of this study.</p><p id="Par58">A limitation of the study was the relatively few samples and a short duration of the meal test, since longer protocols of longer duration including a higher number of samples will reveal a more detailed picture of early as well as late insulin secretion and alpha-cell function as well as NEFA metabolism in response to a meal test [<xref ref-type="bibr" rid="CR51">51</xref>]. The disposition index calculated from the mixed meal test remains to be validated. The assumption is that the beta-cell adaption to ambient insulin resistance follows a hyperbolic law (y&#8201;=&#8201;1/x), and that the product AIR glucose&#8201;&#215;&#8201;Si (the disposition index), therefore, is constant in people with normal beta-cell function. The disposition index in subjects with type 2 diabetes is used to obtain a correct estimate of the beta-cell function it relation to the prevailing degree of insulin resistance of the individual. In the present study we tested for the hyperbolic law in the basal state and found a R<sup>2</sup>&#8201;=&#8201;0.81 suggesting that the disposition index may be valid. However, post hoc power analysis indicates that changes in some of the indices reported, especially regarding ISI<sub>Composite</sub> could flawed due to the study being underpowered. Nevertheless, this explorative study could indicate a more metabolic flexibility of liraglutide treatment than previously acknowledged. The data presented her warrants further experiments in a greater population.</p><p id="Par59">The data presented here were obtained during a relatively short-term treatment period and demonstrated the effects of liraglutide in newly diagnosed patients. Data from real-world clinical practice indicates that the treatments effects we observed are similar to what was observed in clinical trials [<xref ref-type="bibr" rid="CR52">52</xref>]. The present study aimed to reveal treatment effects on pathophysiological features of early T2DM and CAD, yet we speculate that effects in more advanced disease might reveal a different picture, which might add to our knowledge behind the long term positive cardiovascular profile of liraglutide [<xref ref-type="bibr" rid="CR53">53</xref>]. In accordance with clinical trails the side-effect profile of liraglutide was relatively low and comprised mainly of gastrointestinal events, which often resolves within 4&#160;weeks of therapy [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. The present study did not indicate pathophysiological pathways, which could indicate possible adverse long-term effects. Adverse out-come in our trial does not differ substantially from clinical trials [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. Additionally, recent data indicates that liraglutide treatment is not associated with an increased risk for pancreatitis or pancreatic cancer [<xref ref-type="bibr" rid="CR55">55</xref>].</p></sec><sec id="Sec23"><title>Conclusions</title><p id="Par60">In patients with well-controlled T2DM and CAD liraglutide treatment significantly improved disposition index as a measure of beta-cell function but has no effect on alpha-cell function. Combined with metformin, liraglutide reduced ambient insulin levels and improved insulin sensitivity and insulin clearance in a physiologic meal test setting suggesting that liraglutide is as a flexible insulinotropic drug in these patients.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>T2DM</term><def><p id="Par6">type 2 diabetes mellitus</p></def></def-item><def-item><term>NEFA</term><def><p id="Par7">non-esterified fatty acids</p></def></def-item><def-item><term>GLP1-RA</term><def><p id="Par8">glucagon-like peptide-1 receptor agonist</p></def></def-item><def-item><term>CAD</term><def><p id="Par9">coronary artery disease</p></def></def-item><def-item><term>BMI</term><def><p id="Par10">body mass index</p></def></def-item><def-item><term>CV</term><def><p id="Par11">coefficient of variance</p></def></def-item><def-item><term>HOMA-IR</term><def><p id="Par12">homeostasis model assessment of insulin resistance</p></def></def-item><def-item><term>ISR</term><def><p id="Par13">insulin secretion rates</p></def></def-item><def-item><term>ISEC</term><def><p id="Par14">Insulin SECretion (computer program)</p></def></def-item><def-item><term>DI</term><def><p id="Par15">disposition index</p></def></def-item><def-item><term>AUC</term><def><p id="Par16">area under the curve</p></def></def-item><def-item><term>MCRi</term><def><p id="Par17">insulin clearance</p></def></def-item><def-item><term>IDR</term><def><p id="Par18">insulin delivery rate</p></def></def-item><def-item><term>HEXi</term><def><p id="Par19">hepatic extraction of insulin</p></def></def-item><def-item><term>IQR</term><def><p id="Par20">interquartile range</p></def></def-item><def-item><term>SD</term><def><p id="Par21">standard deviation</p></def></def-item><def-item><term>LEAD</term><def><p id="Par22">liraglutide effect and action in diabetes</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>None.</p></ack><notes notes-type="author-contribution"><title>Authors&#8217; contributions</title><p>CA: acquired data, performed the statistical analyses, interpreted data, and drafted and revised the manuscript for important intellectual content and approved the final version. PK, AJ, LRP: acquired data, interpreted data, and revised the manuscript for important intellectual content and approved the final version. OWN, OPK, SM: interpreted data and revised the manuscript for important intellectual content and approved the final version. MF, JJH: performed biochemical analysis, interpreted data, and revised the manuscript for important intellectual content and approved the final version. SBH, AS: conceived and designed the study, interpreted data, and revised the manuscript for important intellectual content and approved the final version. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The study was funded by Novo Nordisk with an unrestricted grant for investigator-initiated studies. Additional funding was provided by: The Danish Heart Foundation, The AP M&#248;ller Foundation, The Department of Internal Medicine, Copenhagen University Hospital, Amager, The Clinical Research Centre, Copenhagen University Hospital, Hvidovre and The Bispebjerg Hospital Research Foundation.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.</p></notes><notes><title>Ethics approval and consent to participate</title><p id="Par61">The study has been approved by the Regional Committee on Biomedical Research Ethics of the Capital Region of Denmark informed consent was obtained from all participants.</p></notes><notes><title>Consent for publication</title><p id="Par62">Not applicable.</p></notes><notes notes-type="COI-statement"><title>Competing interests</title><p id="Par63">CA: Advisory board and lecture fees: Novo Nordisk. PK: none. AJ: none. LRP: share owner: Novo Nordisk. OWN: funding of educational and research tasks from ResMed and participated on advisory boards for Novartis. OPK: none. MF: none. JJH: none. SM: Advisory boards: AstraZeneca; Boehringer Ingelheim; Bristol-Meyers Squibb; Eli Lilly; Intarcia Therapeutics; Johnson &amp; Johnson; Merck Sharp &amp; Dohme; Novartis; Novo Nordisk; Sanofi Aventis. Lecture fees: AstraZeneca; Boehringer Ingelheim; Bristol-Meyers Squibb; Eli Lilly; Merck Sharp &amp; Dohme; Novartis; Novo Nordisk; Sanofi Aventis. Research Grant Recipient: Novo Nordisk. AS: none. SBH: has received funding of educational and research tasks from Novo Nordisk, Abbott, Eli Lilly, Pfizer, Boehringer Ingelheim, Bristol-Meyers Squibb, and Merck Sharp &amp; Dohme.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Defronzo</surname><given-names>RA</given-names></name></person-group><article-title>Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus</article-title><source>Diabetes.</source><year>2009</year><volume>58</volume><issue>4</issue><fpage>773</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.2337/db09-9028</pub-id><pub-id pub-id-type="pmid">19336687</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pratley</surname><given-names>RE</given-names></name><name><surname>Weyer</surname><given-names>C</given-names></name></person-group><article-title>Progression from IGT to type 2 diabetes mellitus: the central role of impaired early insulin secretion</article-title><source>Curr Diab Rep.</source><year>2002</year><volume>2</volume><issue>3</issue><fpage>242</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1007/s11892-002-0090-6</pub-id><pub-id pub-id-type="pmid">12643180</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knop</surname><given-names>FK</given-names></name><name><surname>Aaboe</surname><given-names>K</given-names></name><name><surname>Vilsb&#248;ll</surname><given-names>T</given-names></name><name><surname>V&#248;lund</surname><given-names>A</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>Krarup</surname><given-names>T</given-names></name><etal/></person-group><article-title>Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity</article-title><source>Diabetes Obes Metab</source><year>2012</year><volume>14</volume><issue>6</issue><fpage>500</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1326.2011.01549.x</pub-id><pub-id pub-id-type="pmid">22171657</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baron</surname><given-names>AD</given-names></name><name><surname>Schaeffer</surname><given-names>L</given-names></name><name><surname>Shragg</surname><given-names>P</given-names></name><name><surname>Kolterman</surname><given-names>OG</given-names></name></person-group><article-title>Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics</article-title><source>Diabetes</source><year>1987</year><volume>36</volume><issue>3</issue><fpage>274</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.2337/diab.36.3.274</pub-id><pub-id pub-id-type="pmid">2879757</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuda</surname><given-names>M</given-names></name><name><surname>Defronzo</surname><given-names>RA</given-names></name><name><surname>Glass</surname><given-names>L</given-names></name><name><surname>Consoli</surname><given-names>A</given-names></name><name><surname>Giordano</surname><given-names>M</given-names></name><name><surname>Bressler</surname><given-names>P</given-names></name><etal/></person-group><article-title>Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals</article-title><source>Metabolism.</source><year>2002</year><volume>51</volume><issue>9</issue><fpage>1111</fpage><lpage>1119</lpage><pub-id pub-id-type="doi">10.1053/meta.2002.34700</pub-id><pub-id pub-id-type="pmid">12200754</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boden</surname><given-names>G</given-names></name></person-group><article-title>Interaction between free fatty acids and glucose metabolism</article-title><source>Curr Opin Clin Nutr Metab Care.</source><year>2002</year><volume>5</volume><issue>5</issue><fpage>545</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1097/00075197-200209000-00014</pub-id><pub-id pub-id-type="pmid">12172479</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inzucchi</surname><given-names>SE</given-names></name><name><surname>Bergenstal</surname><given-names>RM</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name><name><surname>Diamant</surname><given-names>M</given-names></name><name><surname>Ferrannini</surname><given-names>E</given-names></name><name><surname>Nauck</surname><given-names>M</given-names></name><etal/></person-group><article-title>Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)</article-title><source>Diabetes Care</source><year>2012</year><volume>35</volume><issue>6</issue><fpage>1364</fpage><lpage>1379</lpage><pub-id pub-id-type="doi">10.2337/dc12-0413</pub-id><pub-id pub-id-type="pmid">22517736</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maruthur</surname><given-names>NM</given-names></name><name><surname>Tseng</surname><given-names>E</given-names></name><name><surname>Hutfless</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>LM</given-names></name><name><surname>Suarez-Cuervo</surname><given-names>C</given-names></name><name><surname>Berger</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis</article-title><source>Ann Intern Med</source><year>2016</year><volume>164</volume><fpage>740</fpage><lpage>751</lpage><pub-id pub-id-type="doi">10.7326/M15-2650</pub-id><pub-id pub-id-type="pmid">27088241</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vitale</surname><given-names>C</given-names></name><name><surname>Mercuro</surname><given-names>G</given-names></name><name><surname>Cornoldi</surname><given-names>A</given-names></name><name><surname>Fini</surname><given-names>M</given-names></name><name><surname>Volterrani</surname><given-names>M</given-names></name><name><surname>Rosano</surname><given-names>GMC</given-names></name></person-group><article-title>Metformin improves endothelial function in patients with metabolic syndrome</article-title><source>J Intern Med.</source><year>2005</year><volume>258</volume><issue>3</issue><fpage>250</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2796.2005.01531.x</pub-id><pub-id pub-id-type="pmid">16115299</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Zeng</surname><given-names>C</given-names></name><name><surname>Liao</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obese</article-title><source>Curr Med Res Opin</source><year>2016</year><volume>32</volume><fpage>1389</fpage><lpage>1396</lpage><pub-id pub-id-type="doi">10.1080/03007995.2016.1176013</pub-id><?supplied-pmid 27052634?><pub-id pub-id-type="pmid">27052634</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holst</surname><given-names>JJ</given-names></name></person-group><article-title>Glucagonlike peptide 1: a newly discovered gastrointestinal hormone</article-title><source>Gastroenterology</source><year>1994</year><volume>107</volume><issue>6</issue><fpage>1848</fpage><lpage>1855</lpage><pub-id pub-id-type="doi">10.1016/0016-5085(94)90831-1</pub-id><pub-id pub-id-type="pmid">7958701</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meier</surname><given-names>JJ</given-names></name></person-group><article-title>GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus</article-title><source>Nat Rev Endocrinol.</source><year>2012</year><volume>8</volume><issue>12</issue><fpage>728</fpage><lpage>742</lpage><pub-id pub-id-type="doi">10.1038/nrendo.2012.140</pub-id><pub-id pub-id-type="pmid">22945360</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vilsb&#248;ll</surname><given-names>T</given-names></name><name><surname>Christensen</surname><given-names>M</given-names></name><name><surname>Junker</surname><given-names>AE</given-names></name><name><surname>Knop</surname><given-names>FK</given-names></name><name><surname>Gluud</surname><given-names>LL</given-names></name></person-group><article-title>Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials</article-title><source>BMJ</source><year>2012</year><volume>344</volume><fpage>d7771</fpage><pub-id pub-id-type="doi">10.1136/bmj.d7771</pub-id><?supplied-pmid 22236411?><pub-id pub-id-type="pmid">22236411</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madsbad</surname><given-names>S</given-names></name><name><surname>Schmitz</surname><given-names>O</given-names></name><name><surname>Ranstam</surname><given-names>J</given-names></name><name><surname>Jakobsen</surname><given-names>G</given-names></name><name><surname>Matthews</surname><given-names>DR</given-names></name><collab>NN2211-1310 International Study Group</collab></person-group><article-title>Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial</article-title><source>Diabetes Care.</source><year>2004</year><volume>27</volume><issue>6</issue><fpage>1335</fpage><lpage>1342</lpage><pub-id pub-id-type="doi">10.2337/diacare.27.6.1335</pub-id><pub-id pub-id-type="pmid">15161785</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zinman</surname><given-names>B</given-names></name><name><surname>Gerich</surname><given-names>J</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name><name><surname>Lewin</surname><given-names>A</given-names></name><name><surname>Schwartz</surname><given-names>S</given-names></name><name><surname>Raskin</surname><given-names>P</given-names></name><etal/></person-group><article-title>Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met&#8201;+&#8201;TZD)</article-title><source>Diabetes Care</source><year>2009</year><volume>32</volume><issue>7</issue><fpage>1224</fpage><lpage>1230</lpage><pub-id pub-id-type="doi">10.2337/dc08-2124</pub-id><pub-id pub-id-type="pmid">19289857</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marre</surname><given-names>M</given-names></name><name><surname>Shaw</surname><given-names>J</given-names></name><name><surname>Br&#228;ndle</surname><given-names>M</given-names></name><name><surname>Bebakar</surname><given-names>WMW</given-names></name><name><surname>Kamaruddin</surname><given-names>NA</given-names></name><name><surname>Strand</surname><given-names>J</given-names></name><etal/></person-group><article-title>Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26&#160;weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)</article-title><source>Diabet Med.</source><year>2009</year><volume>26</volume><issue>3</issue><fpage>268</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1111/j.1464-5491.2009.02666.x</pub-id><pub-id pub-id-type="pmid">19317822</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garber</surname><given-names>A</given-names></name><name><surname>Henry</surname><given-names>R</given-names></name><name><surname>Ratner</surname><given-names>R</given-names></name><name><surname>Garcia-Hernandez</surname><given-names>PA</given-names></name><name><surname>Rodriguez-Pattzi</surname><given-names>H</given-names></name><name><surname>Olvera-Alvarez</surname><given-names>I</given-names></name><etal/></person-group><article-title>Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial</article-title><source>Lancet.</source><year>2009</year><volume>373</volume><issue>9662</issue><fpage>473</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)61246-5</pub-id><pub-id pub-id-type="pmid">18819705</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buse</surname><given-names>JB</given-names></name><name><surname>Rosenstock</surname><given-names>J</given-names></name><name><surname>Sesti</surname><given-names>G</given-names></name><name><surname>Schmidt</surname><given-names>WE</given-names></name><name><surname>Montanya</surname><given-names>E</given-names></name><name><surname>Brett</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)</article-title><source>Lancet</source><year>2009</year><volume>374</volume><issue>9683</issue><fpage>39</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(09)60659-0</pub-id><pub-id pub-id-type="pmid">19515413</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nauck</surname><given-names>M</given-names></name><name><surname>Frid</surname><given-names>A</given-names></name><name><surname>Hermansen</surname><given-names>K</given-names></name><name><surname>Shah</surname><given-names>NS</given-names></name><name><surname>Tankova</surname><given-names>T</given-names></name><name><surname>Mitha</surname><given-names>IH</given-names></name><etal/></person-group><article-title>Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study</article-title><source>Diabetes Care</source><year>2009</year><volume>32</volume><issue>1</issue><fpage>84</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.2337/dc08-1355</pub-id><pub-id pub-id-type="pmid">18931095</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zander</surname><given-names>M</given-names></name><name><surname>Madsbad</surname><given-names>S</given-names></name><name><surname>Madsen</surname><given-names>JL</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name></person-group><article-title>Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study</article-title><source>Lancet</source><year>2002</year><volume>359</volume><issue>9309</issue><fpage>824</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(02)07952-7</pub-id><pub-id pub-id-type="pmid">11897280</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vilsb&#248;ll</surname><given-names>T</given-names></name><name><surname>Brock</surname><given-names>B</given-names></name><name><surname>Perrild</surname><given-names>H</given-names></name><name><surname>Levin</surname><given-names>K</given-names></name><name><surname>Lervang</surname><given-names>H-H</given-names></name><name><surname>K&#248;lendorf</surname><given-names>K</given-names></name><etal/></person-group><article-title>Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus</article-title><source>Diabet Med</source><year>2008</year><volume>25</volume><issue>2</issue><fpage>152</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1111/j.1464-5491.2007.02333.x</pub-id><pub-id pub-id-type="pmid">18201212</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jinnouchi</surname><given-names>H</given-names></name><name><surname>Sugiyama</surname><given-names>S</given-names></name><name><surname>Yoshida</surname><given-names>A</given-names></name><name><surname>Hieshima</surname><given-names>K</given-names></name><name><surname>Kurinami</surname><given-names>N</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><etal/></person-group><article-title>Liraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus</article-title><source>J Diabetes Res.</source><year>2015</year><volume>2015</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1155/2015/706416</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Liu</surname><given-names>A</given-names></name><name><surname>Ariel</surname><given-names>D</given-names></name><name><surname>Abbasi</surname><given-names>F</given-names></name><name><surname>Lamendola</surname><given-names>C</given-names></name><name><surname>Grove</surname><given-names>K</given-names></name><etal/></person-group><article-title>Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study</article-title><source>Diabetologia.</source><year>2014</year><volume>57</volume><issue>3</issue><fpage>455</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1007/s00125-013-3134-3</pub-id><pub-id pub-id-type="pmid">24326527</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pararajasingam</surname><given-names>G</given-names></name><name><surname>H&#248;fsten</surname><given-names>DE</given-names></name><name><surname>L&#248;gstrup</surname><given-names>BB</given-names></name><name><surname>Egstrup</surname><given-names>M</given-names></name><name><surname>Henriksen</surname><given-names>FL</given-names></name><name><surname>Hangaard</surname><given-names>J</given-names></name><etal/></person-group><article-title>Newly detected abnormal glucose regulation and long-term prognosis after acute myocardial infarction: comparison of an oral glucose tolerance test and glycosylated haemoglobin A1c</article-title><source>Int J Cardiol</source><year>2016</year><volume>214</volume><fpage>310</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2016.03.199</pub-id><pub-id pub-id-type="pmid">27085117</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>AYY</given-names></name><name><surname>Lau</surname><given-names>DCW</given-names></name></person-group><article-title>The Canadian Diabetes Association 2013 clinical practice guidelines-raising the bar and setting higher standards!</article-title><source>Can J Diabetes.</source><year>2013</year><volume>37</volume><issue>3</issue><fpage>137</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.jcjd.2013.04.005</pub-id><pub-id pub-id-type="pmid">24070834</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diabetes</surname><given-names>DOF</given-names></name></person-group><article-title>Diagnosis and classification of diabetes mellitus</article-title><source>Diabetes Care</source><year>2013</year><volume>36</volume><issue>Suppl 1</issue><fpage>S67</fpage><lpage>S74</lpage><pub-id pub-id-type="pmid">23264425</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anholm</surname><given-names>C</given-names></name><name><surname>Kumarathurai</surname><given-names>P</given-names></name><name><surname>Klit</surname><given-names>MS</given-names></name><name><surname>Kristiansen</surname><given-names>OP</given-names></name><name><surname>Nielsen</surname><given-names>OW</given-names></name><name><surname>Ladelund</surname><given-names>S</given-names></name><etal/></person-group><article-title>Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol</article-title><source>BMJ Open</source><year>2014</year><volume>4</volume><issue>7</issue><fpage>e005942</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2014-005942</pub-id><?supplied-pmid 25031198?><pub-id pub-id-type="pmid">25031198</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holst</surname><given-names>JJ</given-names></name></person-group><article-title>Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33&#8211;69) of glicentin</article-title><source>Biochem J.</source><year>1982</year><volume>207</volume><issue>3</issue><fpage>381</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1042/bj2070381</pub-id><pub-id pub-id-type="pmid">7165698</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albrechtsen</surname><given-names>NJW</given-names></name><name><surname>Hartmann</surname><given-names>B</given-names></name><name><surname>Veedfald</surname><given-names>S</given-names></name><name><surname>Idorn</surname><given-names>T</given-names></name><name><surname>Feldt-rasmussen</surname><given-names>B</given-names></name><name><surname>Knop</surname><given-names>FK</given-names></name><etal/></person-group><article-title>Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?</article-title><source>Diabetologia</source><year>2014</year><volume>57</volume><issue>9</issue><fpage>1919</fpage><lpage>1926</lpage><pub-id pub-id-type="doi">10.1007/s00125-014-3283-z</pub-id><pub-id pub-id-type="pmid">24891019</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuda</surname><given-names>M</given-names></name><name><surname>DeFronzo</surname><given-names>RA</given-names></name></person-group><article-title>Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp</article-title><source>Diabetes Care</source><year>1999</year><volume>22</volume><issue>9</issue><fpage>1462</fpage><lpage>1470</lpage><pub-id pub-id-type="doi">10.2337/diacare.22.9.1462</pub-id><pub-id pub-id-type="pmid">10480510</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>DR</given-names></name><name><surname>Hosker</surname><given-names>JR</given-names></name><name><surname>Rudenski</surname><given-names>AS</given-names></name><name><surname>Naylor</surname><given-names>BA</given-names></name><name><surname>Treacher</surname><given-names>DF</given-names></name><name><surname>Turner</surname><given-names>RC</given-names></name><etal/></person-group><article-title>Homeostasis model assessment: insulin resistance and fl-cell function from fasting plasma glucose and insulin concentrations in man</article-title><source>Diabetologia</source><year>1985</year><volume>28</volume><issue>7</issue><fpage>412</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1007/BF00280883</pub-id><pub-id pub-id-type="pmid">3899825</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hovorka</surname><given-names>R</given-names></name><name><surname>Soons</surname><given-names>PA</given-names></name><name><surname>Young</surname><given-names>MA</given-names></name></person-group><article-title>ISEC: a program to calculate insulin secretion</article-title><source>Comput Methods Programs Biomed</source><year>1996</year><volume>50</volume><issue>3</issue><fpage>253</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1016/0169-2607(96)01755-5</pub-id><pub-id pub-id-type="pmid">8894385</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergman</surname><given-names>RN</given-names></name><name><surname>Ader</surname><given-names>M</given-names></name><name><surname>Huecking</surname><given-names>K</given-names></name><name><surname>Van Citters</surname><given-names>G</given-names></name></person-group><article-title>Accurate Assessment of beta-cell function&#8212;the hyperbolic correction</article-title><source>Diabetes</source><year>2002</year><volume>51</volume><issue>Suppl 1</issue><fpage>S212</fpage><lpage>S220</lpage><pub-id pub-id-type="doi">10.2337/diabetes.51.2007.S212</pub-id><pub-id pub-id-type="pmid">11815482</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allison</surname><given-names>DB</given-names></name><name><surname>Paultre</surname><given-names>F</given-names></name><name><surname>Maggio</surname><given-names>C</given-names></name><name><surname>Mezzitis</surname><given-names>N</given-names></name><name><surname>Pi-Sunyer</surname><given-names>FX</given-names></name></person-group><article-title>The use of areas under curves in diabetes research</article-title><source>Diabetes Care</source><year>1995</year><volume>18</volume><issue>2</issue><fpage>245</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.2337/diacare.18.2.245</pub-id><pub-id pub-id-type="pmid">7729306</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polonsky</surname><given-names>KS</given-names></name><name><surname>Given</surname><given-names>BD</given-names></name><name><surname>Hirsch</surname><given-names>L</given-names></name><name><surname>Shapiro</surname><given-names>ET</given-names></name><name><surname>Tillil</surname><given-names>H</given-names></name><name><surname>Beebe</surname><given-names>C</given-names></name><etal/></person-group><article-title>Quantitative study of insulin secretion and clearance in normal and obese subjects</article-title><source>J Clin Invest.</source><year>1988</year><volume>81</volume><issue>2</issue><fpage>435</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1172/JCI113338</pub-id><pub-id pub-id-type="pmid">3276729</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haugaard</surname><given-names>SB</given-names></name><name><surname>Andersen</surname><given-names>O</given-names></name><name><surname>V&#248;lund</surname><given-names>A</given-names></name><name><surname>Hansen</surname><given-names>BR</given-names></name><name><surname>Iversen</surname><given-names>J</given-names></name><name><surname>Andersen</surname><given-names>UB</given-names></name><etal/></person-group><article-title>Beta-cell dysfunction and low insulin clearance in insulin-resistant human immunodeficiency virus (HIV)-infected patients with lipodystrophy</article-title><source>Clin Endocrinol</source><year>2005</year><volume>62</volume><issue>3</issue><fpage>354</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2265.2005.02223.x</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahn</surname><given-names>SE</given-names></name><name><surname>Prigeon</surname><given-names>RL</given-names></name><name><surname>McCulloch</surname><given-names>DK</given-names></name><name><surname>Boyko</surname><given-names>EJ</given-names></name><name><surname>Bergman</surname><given-names>RN</given-names></name><name><surname>Schwartz</surname><given-names>MW</given-names></name><etal/></person-group><article-title>Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function</article-title><source>Diabetes.</source><year>1993</year><volume>42</volume><issue>11</issue><fpage>1663</fpage><lpage>1672</lpage><pub-id pub-id-type="doi">10.2337/diab.42.11.1663</pub-id><pub-id pub-id-type="pmid">8405710</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campioni</surname><given-names>M</given-names></name><name><surname>Toffolo</surname><given-names>G</given-names></name><name><surname>Basu</surname><given-names>R</given-names></name><name><surname>Rizza</surname><given-names>RA</given-names></name><name><surname>Cobelli</surname><given-names>C</given-names></name></person-group><article-title>Minimal model assessment of hepatic insulin extraction during an oral test from standard insulin kinetic parameters</article-title><source>Am J Physiol Endocrinol Metab.</source><year>2009</year><volume>297</volume><issue>4</issue><fpage>E941</fpage><lpage>E948</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.90842.2008</pub-id><pub-id pub-id-type="pmid">19671837</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anholm</surname><given-names>C</given-names></name><name><surname>Kumarathurai</surname><given-names>P</given-names></name><name><surname>Pedersen</surname><given-names>LR</given-names></name><name><surname>Nielsen</surname><given-names>OW</given-names></name><name><surname>Kristiansen</surname><given-names>OP</given-names></name><name><surname>Fenger</surname><given-names>M</given-names></name><etal/></person-group><article-title>Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes</article-title><source>Diabetes Obes Metab</source><year>2017</year><volume>19</volume><issue>6</issue><fpage>850</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.1111/dom.12891</pub-id><pub-id pub-id-type="pmid">28124822</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Senn</surname><given-names>S</given-names></name></person-group><source>Cross-over trials in clinical research</source><year>2002</year><edition>2</edition><publisher-loc>Chichester</publisher-loc><publisher-name>Wiley</publisher-name></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumarathurai</surname><given-names>P</given-names></name><name><surname>Anholm</surname><given-names>C</given-names></name><name><surname>Nielsen</surname><given-names>OW</given-names></name><name><surname>Kristiansen</surname><given-names>OP</given-names></name><name><surname>M&#248;lvig</surname><given-names>J</given-names></name><name><surname>Madsbad</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study</article-title><source>Cardiovasc Diabetol.</source><year>2016</year><volume>15</volume><issue>1</issue><fpage>105</fpage><pub-id pub-id-type="doi">10.1186/s12933-016-0425-2</pub-id><?supplied-pmid 27455835?><pub-id pub-id-type="pmid">27455835</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonora</surname><given-names>E</given-names></name><name><surname>Zavaroni</surname><given-names>I</given-names></name><name><surname>Coscelli</surname><given-names>C</given-names></name><name><surname>Butturini</surname><given-names>U</given-names></name></person-group><article-title>Decreased hepatic insulin extraction in subjects with mild glucose intolerance</article-title><source>Metabolism.</source><year>1983</year><volume>32</volume><issue>5</issue><fpage>438</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1016/0026-0495(83)90004-5</pub-id><pub-id pub-id-type="pmid">6341758</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viljanen</surname><given-names>APM</given-names></name><name><surname>Iozzo</surname><given-names>P</given-names></name><name><surname>Borra</surname><given-names>R</given-names></name><name><surname>Kankaanp&#228;&#228;</surname><given-names>M</given-names></name><name><surname>Karmi</surname><given-names>A</given-names></name><name><surname>Lautam&#228;ki</surname><given-names>R</given-names></name><etal/></person-group><article-title>Effect of weight loss on liver free fatty acid uptake and hepatic insulin resistance</article-title><source>J Clin Endocrinol Metab</source><year>2009</year><volume>94</volume><issue>1</issue><fpage>50</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1210/jc.2008-1689</pub-id><pub-id pub-id-type="pmid">18957499</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Saisho</surname><given-names>Y</given-names></name><name><surname>Manesso</surname><given-names>E</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Meguro</surname><given-names>S</given-names></name><name><surname>Irie</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effects of liraglutide monotherapy on beta cell function and pancreatic enzymes compared with metformin in japanese overweight/obese patients with type 2 diabetes mellitus: a subpopulation analysis of the KIND-LM randomized trial</article-title><source>Clin Drug Investig.</source><year>2015</year><volume>35</volume><issue>10</issue><fpage>675</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1007/s40261-015-0331-5</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juhl</surname><given-names>CB</given-names></name><name><surname>Hollingdal</surname><given-names>M</given-names></name><name><surname>Sturis</surname><given-names>J</given-names></name><name><surname>Jakobsen</surname><given-names>G</given-names></name><name><surname>Agers&#248;</surname><given-names>H</given-names></name><name><surname>Veldhuis</surname><given-names>J</given-names></name><etal/></person-group><article-title>Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes</article-title><source>Diabetes</source><year>2002</year><volume>51</volume><issue>2</issue><fpage>424</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.2337/diabetes.51.2.424</pub-id><pub-id pub-id-type="pmid">11812750</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nauck</surname><given-names>MA</given-names></name><name><surname>Kleine</surname><given-names>N</given-names></name><name><surname>Orskov</surname><given-names>C</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>Willms</surname><given-names>B</given-names></name><name><surname>Creutzfeldt</surname><given-names>W</given-names></name></person-group><article-title>Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7&#8211;36 amide) in type 2 (non-insulin-dependent) diabetic patients</article-title><source>Diabetologia</source><year>1993</year><volume>36</volume><issue>8</issue><fpage>741</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1007/BF00401145</pub-id><pub-id pub-id-type="pmid">8405741</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>CK</given-names></name><name><surname>Zinman</surname><given-names>B</given-names></name><name><surname>Choi</surname><given-names>H</given-names></name><name><surname>Connelly</surname><given-names>PW</given-names></name><name><surname>Retnakaran</surname><given-names>R</given-names></name></person-group><article-title>The impact of chronic liraglutide therapy on glucagon secretion in type 2 diabetes: insight From the LIBRA trial</article-title><source>J Clin Endocrinol Metab</source><year>2015</year><volume>100</volume><issue>10</issue><fpage>3702</fpage><lpage>3709</lpage><pub-id pub-id-type="doi">10.1210/jc.2015-2725</pub-id><pub-id pub-id-type="pmid">26230296</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>CK</given-names></name><name><surname>Zinman</surname><given-names>B</given-names></name><name><surname>Choi</surname><given-names>H</given-names></name><name><surname>Connelly</surname><given-names>PW</given-names></name><name><surname>Retnakaran</surname><given-names>R</given-names></name></person-group><article-title>Impact of the glucagon assay when assessing the effect of chronic liraglutide therapy on glucagon secretion</article-title><source>J Clin Endocrinol Metab.</source><year>2017</year><volume>102</volume><fpage>2729</fpage><lpage>2733</lpage><pub-id pub-id-type="doi">10.1210/jc.2017-00928</pub-id><?supplied-pmid 28472325?><pub-id pub-id-type="pmid">28472325</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dandona</surname><given-names>P</given-names></name><name><surname>Ghanim</surname><given-names>H</given-names></name><name><surname>Abuaysheh</surname><given-names>S</given-names></name><name><surname>Green</surname><given-names>K</given-names></name><name><surname>Batra</surname><given-names>M</given-names></name><name><surname>Dhindsa</surname><given-names>S</given-names></name><etal/></person-group><article-title>Decreased insulin secretion and incretin concentrations and increased glucagon concentrations after a high-fat meal when compared with a high-fruit and -fiber meal</article-title><source>Am J Physiol Endocrinol Metab</source><year>2015</year><volume>308</volume><issue>3</issue><fpage>E185</fpage><lpage>E191</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00275.2014</pub-id><pub-id pub-id-type="pmid">25406260</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alsalim</surname><given-names>W</given-names></name><name><surname>Tura</surname><given-names>A</given-names></name><name><surname>Pacini</surname><given-names>G</given-names></name><name><surname>Omar</surname><given-names>B</given-names></name><name><surname>Bizzotto</surname><given-names>R</given-names></name><name><surname>Mari</surname><given-names>A</given-names></name><etal/></person-group><article-title>Mixed meal ingestion diminishes glucose excursion in comparison with glucose ingestion via several adaptive mechanisms in people with and without type 2 diabetes</article-title><source>Diabetes Obes Metab</source><year>2016</year><volume>18</volume><issue>1</issue><fpage>24</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1111/dom.12570</pub-id><pub-id pub-id-type="pmid">26354383</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boston</surname><given-names>RC</given-names></name><name><surname>Moate</surname><given-names>PJ</given-names></name></person-group><article-title>NEFA minimal model parameters estimated from the oral glucose tolerance test and the meal tolerance test</article-title><source>Am J Physiol Regul Integr Comp Physiol</source><year>2008</year><volume>295</volume><issue>2</issue><fpage>R395</fpage><lpage>R403</lpage><pub-id pub-id-type="doi">10.1152/ajpregu.90317.2008</pub-id><pub-id pub-id-type="pmid">18565832</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostawal</surname><given-names>A</given-names></name><name><surname>Mocevic</surname><given-names>E</given-names></name><name><surname>Kragh</surname><given-names>N</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name></person-group><article-title>Clinical Effectiveness of liraglutide in type 2 diabetes treatment in the real-world setting: a systematic literature review</article-title><source>Diabetes Ther.</source><year>2016</year><volume>7</volume><issue>3</issue><fpage>411</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1007/s13300-016-0180-0</pub-id><pub-id pub-id-type="pmid">27350545</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marso</surname><given-names>SP</given-names></name><name><surname>Daniels</surname><given-names>GH</given-names></name><name><surname>Brown-Frandsen</surname><given-names>K</given-names></name><name><surname>Kristensen</surname><given-names>P</given-names></name><name><surname>Mann</surname><given-names>JFE</given-names></name><name><surname>Nauck</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Liraglutide and cardiovascular outcomes in type 2 diabetes</article-title><source>N Engl J Med.</source><year>2016</year><volume>375</volume><issue>4</issue><fpage>311</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1603827</pub-id><pub-id pub-id-type="pmid">27295427</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blonde</surname><given-names>L</given-names></name><name><surname>Russell-Jones</surname><given-names>D</given-names></name></person-group><article-title>The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1&#8211;5 studies</article-title><source>Diabetes Obes Metab</source><year>2009</year><volume>11</volume><issue>Suppl 3</issue><fpage>26</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1326.2009.01075.x</pub-id><pub-id pub-id-type="pmid">19878259</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><mixed-citation publication-type="other">Funch D, Mortimer K, Ziyadeh NJ, Seeger JD, Li L, Norman H, et al. Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population. Diabetes Obes Metab. 2019; <bold>(Epub ahead)</bold>.</mixed-citation></ref></ref-list></back></article>